EFFICACY (PFS) DEMONSTRATED IN PHASE III CLINICAL STUDY

VCC-001 HAS ALREADY DEMONSTRATED SIGNIFICANT CLINICAL EFFICACY IN PHASE III WITH 553 PATIENTS

5-year progression-free survival rate for patients at all tumour stages was 77.4% in the vaccine group and 67.8% in the control group (p=0.0204), and 70-month progression-free survival rates were 72% in the vaccine group and 59.3% in the control group

Median time to tumour progression was not reached in either group. The time until 25% of patients had progressed was 63.2 months for patients in the vaccine group versus 42.1 months for those in the control group



Number at risk

Vaccine	177	165	154	142	124	62	0
Control	202	176	159	151	132	72	1

PROGRESSION-FREE SURVIVAL FOR ALL ELIGIBLE PATIENTS (INTENTION-TO-TREAT POPULATION)



Number at risk

Vaccine	177	165	154	142	124	62	0
Control	202	176	159	151	132	72	1

PROGRESSION-FREE SURVIVAL FOR ELIGIBLE PATIENTS WITH T3 TUMOURS (INTENTION-TO-TREAT POPULATION)

VCC-001 SHOWED AN INCREASE OF 36 MONTH IN PFS VS CONTROL GROUP

Jocham et al., The Lancet, Vol 363, 2004, Feb. 21: 597